Gyre Therapeutics, Inc.
corporate_fare Company Profile
Gyre Therapeutics, Inc. (NASDAQ:GYRE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for GYRE at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for GYRE spans 8-K, 10-Q, 8-K/A, S-3.
Recent high-impact activity:
- Gyre Q3 Revenue $32.9M, Swings to $2.5M Loss; F351 NMPA Decision Due by 1Q27
- Q3 Revenue Climbs to $32.9M as ETUARY Sales Grow, 2026 Outlook Reaffirmed
- Gyre Posts Q2 Revenue of $29.1M, Reaffirms Full-Year Outlook, and Flags GNI Japan Share Pledge
- Gyre Therapeutics Posts Q2 2026 Revenue of $29.1M, Reaffirms Full-Year Outlook, and Spotlights F351 NDA Acceptance
- Gyre Therapeutics Amends 8-K to Include Cullgen Financials and Pro Forma Statements
Financial Snapshot
Short Interest & Short Volume
14.22 days to coverFINRA reported short interest of 2,241,208 shares in GYRE as of the October 30, 2026 settlement, a 16.3% increase from the prior period — about 14.2 days to cover at its recent average daily volume. On November 20, 2026, 76.8% of GYRE volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for GYRE, detected from its recent SEC filings · based on capital-structure filings through 2026-06-22.
Resale Registration Filed · Shares from Cullgen Acquisition
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →